Phase I Trial of Intravenous Administration of Vesicular Stomatitis Virus Genetically Engineered to Express Thyroidal Sodium Iodide Symporter (NIS) and Human Interferon Beta (hIFNb), in Patients With Metastatic or Recurrent Endometrial Cancer
Latest Information Update: 31 Oct 2024
At a glance
- Drugs VSV-IFNbeta-NIS (Primary) ; Ruxolitinib; Technetium-99m
- Indications Adenocarcinoma; Carcinoma; Endometrial cancer; Sarcoma
- Focus Adverse reactions
Most Recent Events
- 02 Aug 2024 Planned End Date changed from 15 Jul 2024 to 15 Jul 2025.
- 22 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 29 Aug 2023 Status changed from active, no longer recruiting to recruiting.